CA19-9 in Combination with Methylated HOXA1 and SST Is Useful to Diagnose Stage I Pancreatic Cancer
| Autor: | Yutaka Suehiro, Shigeyuki Suenaga, Yuki Kunimune, Shoko Yada, Kaori Hamamoto, Takanori Tsuyama, Shogo Amano, Hiroto Matsui, Shingo Higaki, Ikuei Fujii, Chieko Suzuki, Tomomi Hoshida, Toshihiko Matsumoto, Yuko Fujimoto, Seiji Kaino, Keiko Shinjo, Yutaka Kondo, Isao Sakaida, Taro Takami, Hiroaki Nagano, Takahiro Yamasaki |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Oncology. 100:674-684 |
| ISSN: | 1423-0232 0030-2414 |
| DOI: | 10.1159/000527342 |
| Popis: | Introduction: We previously developed a novel methylation assay, the combined restriction digital PCR (CORD) assay, consisting of treatment of DNA with methylation-sensitive restriction enzymes and droplet digital PCR. Methods: In this study, we assessed the diagnostic performance of serum methylated Homeobox A1 (mHOXA1) and methylated somatostatin (mSST) using the CORD assay in combination with CA19-9 for pancreatic cancer using serum samples from 82 healthy individuals, 13 patients with benign pancreatic disease, 3 patients with branched-duct intraductal papillary mucinous neoplasm, and 91 patients with pancreatic cancer. Results: For the single marker tests, sensitivity for all stages of pancreatic cancer, stage I cancer, and specificity were, respectively, 71.4%, 50.0%, and 94.9% for CA19-9; 51.6%, 68.8%, and 90.8% for mHOXA1; and 50.1%, 68.8%, and 94.9% for mSST. Those for the combined marker tests were, respectively, 86.8%, 81.3%, and 85.7% for combined mHOXA1 and CA19-9; 86.8%, 87.5%, and 89.8% for combined mSST and CA19-9; and 89.0%, 87.5%, and 85.7% for all three markers combined. Conclusion: The combination of mHOXA1 and mSST with CA19-9 appears to be useful to detect pancreatic cancer even at an early stage. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|